Temporal Trend of Comorbidity and Increasing Impacts on Mortality, Length of Stay, and Hospital Costs of First Stroke in Tianjin, North of China

Ruixiao Hao  
Tianjin Medical University Second Hospital

Xuemei Qi  
Tianjin Medical University Second Hospital

Xiaoshuang Xia  
Tianjin Medical University Second Hospital

Lin Wang  
Tianjin Medical University Second Hospital

Xin Li (lixinsci@126.com)  
Tianjin Medical University Second Hospital  
https://orcid.org/0000-0002-2977-5075

Research Article

Keywords: stroke, comorbidity, mortality, length of stay, cost

Posted Date: August 13th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-796597/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose: Stroke patients have a high incidence of comorbidity. Our study aimed to explore the trend of comorbidity among patients with first stroke from 2010 to 2020, and the influence of comorbidity on admission mortality, length of stay and hospitalization costs. 5988 eligible patients were enrolled in our study, and divided into 4 comorbidity burden groups according to Charlson comorbidity index (CCI): none, moderate, severe, very severe. Survival analysis was expressed by Kaplan - Meier curve. Cox regression model was used to analyze the effect of comorbidity on 7-day and in-hospital mortality. Generalized linear model (GLM) was used to analyze the association between comorbidity and hospitalization days and cost.

Results: Compared to patients without comorbidity, those with very severe comorbidity were more likely to be male (342, 57.7%), suffer from ischemic stroke (565, 95.3%), afford higher expense (Median, 19339.3RMB, IQR13020.7-27485.9RMB), and have a higher in-hospital mortality (60, 10.1%). From 2010 to 2020, proportion of patients with severe and very severe comorbidity increased 12.9%. The heaviest comorbidity burden increased the risk of 7-day mortality (adjusted hazard ratio, 3.51, 95% CI, 2.22-5.53) and in-hospital mortality (adjusted hazard ratio, 3.83, 95% CI, 2.70-5.45). Patients with very severe comorbidity had a 12% longer LOS and extra 27% expense than those without comorbidity.

Conclusion: Comorbidity burden showed an increasing trend year in past eleven years. The heavy comorbidity burden increased in-hospital mortality, LOS, and hospitalization cost, especially in patients aged 55 years or more.

Introduction

Stroke is a leading cause of death and disability worldwide with substantial economic burden of treatment and post-stroke care. In general, age-standardized death rates and incidence of stroke have a decreased tendency globally except in eastern Asia and southern Africa. Over the past decades, China has undergone a rapid speed of demographic and epidemiological transitions. Instead of infectious diseases, non-communicable diseases has generally increased, such as stroke, chronic obstructive pulmonary disease, lung cancer and so on. Stroke is still a serious public health problem in China with a high level of incidence, prevalence, disability rate, and mortality. Compared with the developed countries, stroke has its own unique epidemiological features based on China’s demographic characteristics.

According to the 2010 census, China has become one of the fastest aging countries with a proportion of people aged 65 years and older accounting for 8.9% (approximately 119 million). By 2050, there will be an aging population in China as large as in the developed countries or more. With a rapid speed of aging, age-specific prevalence rate of stroke in our country increased with age no matter sex or types of stroke, with a remarkable increase in people aged 50 years and older. Ischemic stroke is the most common subtype which accounts for 80% of all stroke. And the hazard factors of stroke also affect prevalence of many chronic diseases (e.g., myocardial infarction, diabetes, chronic obstructive pulmonary disease, and cancer). Previous studies conducted in developed countries illustrated comorbidity is a strong factor affecting short- and long-term mortality of post-stroke, as well as economic burden in admission. However, few studies are devoted to the relationship between stroke and comorbidity in the condition of an aging population with increasing prevalence of comorbidity in China. It is extremely important to monitor and manage stroke and comorbidity.

We therefore conducted a population-based study to explore three interesting events among first stroke patients between 2010 and 2020: the development trends of comorbidity; the effect of comorbidity on stroke in-hospital mortality and social and economic burden causing by comorbidity (including length of hospital stay and inpatient costs).

Materials And Methods

Data sources

The Second Hospital of Tianjin Medical University, located in the north of China, is a general tertiary hospital with a level of medical care. Each patient admitted to our hospital was given a unique admission number based on identification card number, which is convenient to know about the reasons of every visiting hospital. The diagnostic information of each outpatient visit or hospital discharge is recorded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and
ICD-10. The record contained the basic information of patients including name, sex, information on birth date, hospital admission numbers, medical insurance methods, length of stay (LOS), hospitalization expenses, one primary diagnosis and one or more secondary diagnoses, and vital status. Because ICD codes can't distinguish the severity of the disease, we obtained the details of admission patients like the severity of liver and renal function from Electronic Medical Records System. The main insurance schemes in China are the Urban Employee Basic Medical Insurance (UEBMI), the Urban Residence Basic Medical Insurance, and the New Rural Cooperative Medical Scheme, which covered over 92 percentage of the total population by 2011. The first two programs cover urban working and retired employees and urban residents without formal employment, respectively. The last covers rural residents. The insurance programs in Tianjin are the UEBMI and the Urban Residence Basic Medical Insurance.

**Study Cohort**

We performed a retrospective analysis on the records of all patients, aged ≥ 18 years, admitted to the department of neurology in our hospital for acute stroke between 1 January 2010 and 31 December 2020. A total of 10494 patients with the primary diagnosis of stroke were screened using the ICD diagnosis codes with stroke. After excluding the population diagnosed with a history of stroke, eligible patients were enrolled in our study cohort, who hospitalized for first-time stroke.

All the diagnoses of stroke were independently made by two experienced neurologists to ensure the accuracy of diagnoses. All patients performed computed tomography (CT) or magnetic resonance imaging (MRI).

**Comorbidity**

We acquired the comorbidities in accordance with primary and secondary diagnoses. To avoid the confusion that whether comorbidities were related to stroke, we eliminated patients diagnosed with the history of cerebrovascular disease and hemiplegia. We calculated the Charlson comorbidity index (CCI), a simple, wildly, and valid method to evaluate the risk of death from comorbid disease. The total CCI scores were the weighted sum of each comorbidity, which was assigned between 1 and 6 points respectively. We divided patients into four groups based on the total scores: none (CCI = 0), moderate (CCI = 1), severe (CCI = 2), and very severe (CCI = 3 or higher).

**Outcome Variables**

We paid attention to two primer outcomes: the all-cause mortality within 7 days and the all-cause in-hospital mortality. The 7-day mortality rate was equal to the number of deaths over the total number of admitted cases at the 7th day after admission. The in-hospital death rate was calculated as the ratio of death numbers to the total of admitted cases during the period from the admission date to the date of separation (death or discharged alive). The second outcomes were length of stay expressed in days (in days) and inpatient costs (in RMB). The length of stay (LOS) was defined as the day from the admission to death or discharge.

**Statistical analyses**

We performed statistical analyses to summarize basic characteristics of patients. Firstly, the univariate analysis was utilized on baseline characteristics of patients. Categorical variables were presented as count (percentage), and compared using the Pearson χ² test or Fisher's exact test. Continuous variables with normal distribution were expressed as mean ± standard deviation (SD), and differences in age among different groups were compared with one-way analysis of variance (ANOVA). Continuous variables without normal distribution were expressed as median (interquartile range, IQR), and calculated by Kruskal-Wallis rank test. Kaplan-Meier methods were used for survival curve plotting among different comorbidity burden groups and differences were examined by using the log-rank test. To assess the relationship between comorbidity category and the 7-day as well as inpatient mortality, we performed Cox proportional hazards regression model controlling the confounding factors. Results were presented as hazard ratio (HR) with 95% confidence intervals (CIs) using patients without comorbidity as reference. After performing univariate Cox regression, we further analyzed the covariates with a univariable P value < 0.05 using the multivariable Cox model.

LOS data were over-dispersed distribution and the cost data represented the right-skewed distribution. A generalized linear model (GLM) was conducted to evaluate the LOS and inpatient cost. GLM with a negative binomial distribution was used to analyze LOS, whereas GLM with log link and gamma distribution was performed to assess in-hospital cost differences among groups. All statistical models were conducted by SPSS 25.0 software or GraphPad prism 8.0. Statistical significance was rejection of Null hypothesis with a 2-sided probability value of < 0.05.
Results

Patient Characteristics

A total of 5988 were included between in 1 January 2010 and 31 December 2020 (Table 1). Of all patients with mean age of 69.3 years, patients aged ≥ 65 years accounted for 63.5%. Most had ischemic stroke (5751, 96%) with mean age 69.5 years, whereas 237 (4%) were hemorrhagic stroke with a younger average age of 66.1 years. The proportion of first stroke was higher in males (58.4%) than in females (41.6%). All patients were divided into four groups in terms of comorbidity categories: none (2878, 48.1%), moderate (1972,32.9%), severe (545, 9.1%), very severe (593, 9.9%). The patients with heavier comorbidity burden were likely to be elderly male, and with a higher hospitalization cost. It was fortunate that a high proportion of medical insurance system can help reduce the economic burden of illness with basic medical insurance for urban workers as the dominant mode, whereas self-pay accounted for 9.6%. There was no difference in season and week among groups in our study.
Table 1
Sociodemographic and Clinical Characteristics of Patients Admitted for First Stroke

| Variables                          | Total (n = 5988) | Comorbidity category | P value |
|------------------------------------|-----------------|----------------------|---------|
|                                    |                 | None (n = 2878)      | Moderate (n = 1972) | Severe (n = 545) | Very severe (n = 593) |
| Age (mean ± SD)                    | 69.3 ± 12.4     | 68.3 ± 12.7          | 69.6 ± 12.1        | 73.5 ± 11.2       | 70.2 ± 12.3           | <0.001              |
| Sex, N (%)                         |                 |                      |                    |                    |                      |                     |
| Female                             | 2493 (41.6)     | 1096 (38.1)          | 892 (45.2)         | 254 (46.6)        | 251 (42.3)           | <0.001              |
| Age group, N (%)                   |                 |                      |                    |                    |                      | <0.001              |
| 18–34 years                        | 23 (0.4)        | 12 (0.4)             | 5 (0.3)            | 2 (0.4)           | 4 (0.7)              |                     |
| 35–44 years                        | 121 (2.0)       | 74 (2.6)             | 31 (1.6)           | 7 (1.3)           | 9 (1.5)              |                     |
| 45–54 years                        | 627 (10.5)      | 339 (11.8)           | 213 (10.8)         | 23 (4.2)          | 52 (8.3)             |                     |
| 55–64 years                        | 1412 (23.6)     | 757 (26.3)           | 444 (22.5)         | 83 (15.2)         | 128 (21.6)           |                     |
| 65–74 years                        | 1431 (23.9)     | 645 (22.4)           | 499 (25.3)         | 142 (26.1)        | 145 (24.5)           |                     |
| 75–84 years                        | 1757 (29.3)     | 776 (27.0)           | 589 (29.9)         | 202 (37.1)        | 190 (32.0)           |                     |
| ≥ 85 years                         | 617 (10.3)      | 275 (9.6)            | 191 (9.7)          | 86 (15.8)         | 65 (11.0)            |                     |
| Comorbidities, N (%)               |                 |                      |                    |                    |                      |                     |
| Hypertension                       | 4758 (79.5)     | 2264 (78.7)          | 1578 (80.0)        | 429 (78.7)        | 487 (82.1)           | 0.235               |
| Atrial fibrillation or flutter     | 858 (14.3)      | 353 (12.3)           | 285 (14.5)         | 118 (21.7)        | 102 (17.2)           | <0.001              |
| Myocardial infarction              | 365 (6.1)       | 0 (0)                | 132 (6.7)          | 153 (28.1)        | 80 (13.5)            | <0.001              |
| Congestive heart failure           | 524 (8.8)       | 0 (0)                | 185 (9.4)          | 157 (28.8)        | 182 (30.7)           | <0.001              |
| Peripheral vascular disease        | 256 (4.3)       | 0 (0)                | 76 (3.9)           | 68 (12.5)         | 112 (18.9)           | <0.001              |
| Dementia                           | 86 (1.4)        | 0 (0)                | 52 (2.6)           | 27 (5.0)          | 7 (1.2)              | <0.001              |
| Chronic Pulmonary disease          | 48 (0.8)        | 0 (0)                | 20 (1.0)           | 17 (3.1)          | 11 (1.9)             | <0.001              |
| Connective tissue disease          | 93 (1.6)        | 0 (0)                | 52 (2.6)           | 23 (4.2)          | 18 (3.0)             | <0.001              |
| Ulcer disease                      | 106 (1.8)       | 0 (0)                | 46 (2.3)           | 33 (6.1)          | 27 (4.6)             | <0.001              |
| Mild liver disease                 | 59 (1.0)        | 0 (0)                | 22 (1.1)           | 20 (3.7)          | 17 (2.9)             | <0.001              |
| Diabetes without end-organ damage  | 2084 (34.8)     | 0 (0)                | 1387 (70.3)        | 268 (49.2)        | 429 (72.3)           | <0.001              |

*Human immunodeficiency virus and acquired immune deficiency syndrome was omitted from the table owing to its low Prevalence (0.0%).
| Variables                                      | Total (n = 5988) | Comorbidity category | P value |
|-----------------------------------------------|------------------|-----------------------|---------|
|                                               | None (n = 2878)  | Moderate (n = 1972)   |         |
|                                               | Severe (n = 545) | Very severe (n = 593) |         |
| Diabetes with end-organ damage                | 223(3.7)         | 0(0)                  | 0(0)    | 223(37.6) | <0.001 |
| Moderate to severe renal disease              | 228(3.8)         | 0(0)                  | 71(13.0)| 157(26.5) | <0.001 |
| Nonmetastatic solid tumor                     | 201(3.4)         | 0(0)                  | 88(16.1)| 113(19.1) | <0.001 |
| Leukemia                                      | 7(0.1)           | 0(0)                  | 2(0.4) | 5(0.8)    | <0.001 |
| Lymphoma                                      | 3(0.1)           | 0(0)                  | 1(0.2) | 2(0.3)    | 0.003  |
| Moderate to severe liver disease              | 74(1.2)          | 0(0)                  | 0(0)   | 74(12.5)  | <0.001 |
| Metastatic cancer                             | 16(0.3)          | 0(0)                  | 0(0)   | 16(2.7)   | <0.001 |
| Stroke type, N (%)                            |                 |                       | <0.001 |
| Ischemic stroke                               | 5751(96.0)       | 2749(95.5)            | 1924(97.6)| 513(94.1)| 565(95.3)|
| Hemorrhagic stroke                            | 237(4.0)         | 129(4.5)              | 48(2.4)| 32(5.9)   | 28(4.7)|
| Season, N (%)                                 |                 |                       | 0.263  |
| Spring                                        | 1481(24.7)       | 707(24.6)             | 518(26.3)| 133(24.4)| 123(20.7)|
| Summer                                        | 1519(25.4)       | 756(26.3)             | 475(24.1)| 136(25.0)| 152(25.6)|
| Fall                                          | 1484(24.8)       | 716(24.9)             | 480(24.3)| 136(25.0)| 152(25.6)|
| Winter                                        | 1504(25.1)       | 699(24.3)             | 499(25.3)| 140(25.7)| 166(28.0)|
| Week, N (%)                                   |                 |                       | 0.464  |
| Weekend                                       | 1625(27.1)       | 796(27.7)             | 510(25.9)| 155(28.4)| 164(27.1)|
| Weekday                                       | 4363(72.9)       | 2082(72.3)            | 1462(74.1)| 390(71.6)| 429(72.3)|
| Payer, N (%)                                  |                 |                       | <0.001 |
| Urban Employee Basic Medical Insurance        | 4540(75.8)       | 2139(74.3)            | 1538(78.0)| 403(73.9)| 460(77.6)|
| Urban Residence Basic Medical Insurance       | 874(14.6)        | 422(14.7)             | 256(13.0)| 100(18.3)| 96(16.2)|
| Self-Pay                                      | 571(9.6)         | 317(11.0)             | 178(9.0)| 42(7.7)   | 37(6.2)|
| COST median (IQR)                             | 15151.7(10649.7-22584.9)| 14160.4(10020.2-21148.3)| 15243.5(11074.0-22610.8)| 17936.7(11980.8-25980.4)| 19339.3(13020.7-27485.9)| <0.001 |

*Human immunodeficiency virus and acquired immune deficiency syndrome was omitted from the table owing to its low Prevalence (0.0%).
The tendency of comorbidity state and different age groups by calendar year was visually displayed based on the proportion of first stroke (supplemental Fig. 1). From 2010 to 2020, the proportion of patients without comorbidity decreased 14.6 percentage points (from 54.7–40.1%), while there was a noticeable 12.9 percent increase in patients with very severe comorbidity (from 3.3–16.2%) (Supplemental table 1). Proportions of patients aged 55–84 years were higher far more than any other group. Among those, the elderly in the 65–84 years age group almost account for approximately 50%, and the proportion of the oldest age group (≥85 years) in 2020 increased 8.3% compared to 2010 (Supplemental table 1). Although male was predominated, there was no sex difference among different year groups (Supplemental table 1).

**Mortality**

There was a total of 249 (4.2%) death in the hospital, with 50.2% (n = 125) of women. For in-hospital mortality, the age of the patients was 78.4 ± 9.6 years with 3.9% (223/5528) in ischemic stroke and 69.7 ± 14.9 years with 11.0% (26/211) in hemorrhage stroke. In-hospital mortality in patients with very severe comorbidity was the most (n = 60; 10.1%), those without comorbidity the least (n = 65; 2.3%). The Kaplan-Meier survival curves showed that the in-hospital mortality was higher among patients with severe and very severe comorbidity than patients without comorbidity (supplemental Fig. 2a). And the same tendency was observed in the 7-day mortality (supplemental Fig. 2b).

Cox regression analysis identified several risk factors of in-hospital mortality (Supplemental table 2). Model 1 was adjusted for age and sex. Model 2 was adjusted for sex, age, season, stroke types. The two models illustrated the consistent result that patients with any comorbidity category had a higher risk of in-hospital mortality compared to those without comorbidity, with the highest risk among those with very severe comorbidity (adjusted hazard ratio in model 2, HR = 3.83, 95% CI, 2.70–5.45) (Table 2). Similar methods to the in-hospital mortality rate (Supplemental table 3), the tendency of increased risk appeared only in patients with severe and very severe comorbidity in 7-day mortality (Table 2).
Table 2
Comparison of Mortality Risks Between Patients Admitted for First Stroke with Different Comorbidity Categories

|                      | Univariable Analysis | Multivariable Analysis: Model 1 | Multivariable Analysis: Model 2 |
|----------------------|----------------------|---------------------------------|---------------------------------|
|                      | HR (95% CI)          | aHR* (95% CI)                   | aHR* (95% CI)                   |
|                      | P value              | P value                         | P value                         |
| In-hospital mortality|                      |                                 |                                 |
| None                 | 1.00                 | 1.00                            | 1.00                            |
| Moderate             | 1.53(1.10–2.14)      | 0.013                           | 1.48(1.06–2.07)                 | 0.022 |
|                      | <0.01                |                                 |                                 |
| Severe               | 3.50(2.42–5.07)      | <0.001                          | 2.88(1.98–4.17)                 | <0.001 |
| Very severe          | 3.95(2.78–5.62)      | <0.001                          | 3.84(2.70–5.46)                 | <0.001 |
| 7-day mortality      |                      |                                 |                                 |
| None                 | 1.00                 | 1.00                            | 1.00                            |
| Moderate             | 1.24(0.80–1.93)      | 0.330                           | 1.48(1.06–2.07)                 | 0.448 |
|                      | <0.001               |                                 |                                 |
| Severe               | 3.61(2.52–5.78)      | <0.001                          | 2.88(1.98–4.17)                 | <0.001 |
| Very severe          | 3.77(2.40–5.94)      | <0.001                          | 3.84(2.70–5.46)                 | <0.001 |

aHR indicates adjusted hazard ratio; HR, hazard ratio.

*Model 1: aHR was calculated with adjustments for age and sex; Model 2: aHR was calculated with adjustments for age, sex, season, stroke type.

For patients with ischemic stroke, the increased in-hospital and 7-day death risk among comorbidity groups was consistent with those with stroke (Table 3). Different from ischemic stroke, the increased risk only occurred to those with severe and very severe comorbidity when compared to those without comorbidity in hemorrhage stroke. When patients without comorbidity were as reference, the hazard ratio is higher in hemorrhage stroke than ischemic stroke (Table 3). We further conducted an age-stratified analysis, severe and very severe comorbidity burden had the strongest effect on in-hospital mortality in the elder groups with age ≥ 55 years (Supplemental table 4). Also, season is a significant risk factor of in-hospital death with the highest inpatient mortality in winter. We further stratified seasons and found that the heaviest comorbidity burden was related to in-hospital death in each stratify (Supplemental table 5).
Table 3
Comparison of Mortality Risks Between Patients Admitted for Different Stroke Type with Different Comorbidity Categories

| Comorbidity burden*                  | In-hospital Mortality | 7-day Mortality |
|--------------------------------------|-----------------------|-----------------|
|                                      | Univariable Analysis  | Multivariable Analysis | Univariable Analysis  | Multivariable Analysis | Univariable Analysis  | Multivariable Analysis |
|                                      | HR (95% CI)          | P value          | aHR (95% CI)          | P value          | HR (95% CI)          | aHR (95% CI)          | P value          | aHR (95% CI)          | P value |
| Ischemic stroke                      |                       |                  |                       |                  |                       |                  |                  |                  |                  |
| None                                 | 1.00                  | 1.00             | 1.00                  | 1.00             | 1.00                  | 1.00             | 1.00             | 1.00             | 1.00             |
| Moderate                             | 1.62(1.14–2.30)      | 0.007            | 1.57(1.11–2.23)      | 0.012            | 1.34(0.84–2.13)      | 0.215            | 1.27(0.80–2.02)   | 0.310            |
| Severe                               | 3.38(2.27–5.04)      | <0.001           | 2.68(1.79–4.00)      | <0.001           | 3.51(2.10–5.87)      | <0.001           | 3.32(2.02–5.45)   | <0.001           |
| Very severe                          | 3.95(2.71–5.75)      | <0.001           | 3.59(2.18–5.89)      | <0.001           | 3.32(2.02–5.45)      | <0.001           |
| Hemorrhagic stroke                   |                       |                  |                       |                  |                       |                  |                  |                  |                  |
| None                                 | 1                     | 1                | 1.00                  | 1.00             | 1.00                  | 1.00             |
| Moderate                             | 0.98(0.26–3.70)      | 0.975            | 0.92(0.24–3.49)      | 0.904            | 0.88(0.18–4.38)      | 0.880            | 0.80(0.16–4.00)   | 0.790            |
| Severe                               | 3.91(1.45–10.56)     | 0.007            | 3.97(1.47–10.70)     | 0.006            | 3.49(1.07–11.44)     | 0.039            | 3.51(1.07–11.52)  | 0.038            |
| Very severe                          | 3.88(1.40–10.76)     | 0.009            | 3.95(1.42–10.99)     | 0.008            | 4.78(1.54–14.84)     | 0.007            | 4.88(1.57–15.14)  | 0.006            |

aHR indicates adjusted hazard ratio; HR, hazard ratio.

* Four categories of comorbidity were defined based on Charlson Comorbidity Index scores of 0 (none), 1 (moderate), 2 (severe), and 3 or more (very severe).

The risk of in-hospital death influenced by individual disease in detail was presented in Fig. 1. It was pneumonia, congestive heart failure, peripheral vascular disease, moderate to severe renal and liver disease that were strongly associated with in-hospital mortality. The in-hospital mortality with pneumonia was 15 times higher than without pneumonia. The inpatient mortality was increased 2.3-fold for moderate to severe renal and liver disease. However, there were no connection between the inpatient death risk and the other comorbidity factors such as myocardial infarction, atrial fibrillation or flutter, chronic pulmonary disease, and diabetes with or without end-organ damage. The fatality rate during the first one-week was 2.4% (142/5846). Patients with higher death risk tended to hemorrhage stroke and were more likely to suffer from pneumonia, moderate and severe renal and liver disease, or congestive heart failure (Supplemental table 6).

**Length of Stay**

The median duration of LOS was 14 (IQR: 11–15) days (Table 1). While the unadjusted median LOS of hemorrhage stroke was 15 (IQR: 12–21) days, longer than that of ischemic patients, which is same as the stroke. Table 4 showed the effect of sociodemographic, clinical characteristics on LOS. There was no difference in LOS between male and female. Those with more comorbidities and older
had a tendency of longer LOS. The length of the hospital stay was not affected by admission time whether on the week or in any season. And there was no difference in terms of payment on LOS.
Table 4
Estimated Length of Stay with 95% Confidence Intervals by Patient Characteristics

|                      | Model 1 |                | Model 2 |                |
|----------------------|---------|----------------|---------|----------------|
|                      | β (95% CI) | P value       | β (95% CI) | P value       |
| **Sex**              |         |                |         |                |
| Male                 | 1.00    | -              | 1.00    | -              |
| Female               | 1.02(0.97–1.07) | 0.515       | -      | -              |
| **Age group**        |         |                |         |                |
| 18–34 years          | 0.79(0.51–1.22) | 0.284       | 0.77(0.51–1.19) | 0.243       |
| 35–44 years          | 0.80(0.66–0.99) | 0.036       | 0.80(0.65–0.98) | 0.034       |
| 45–54 years          | 0.84(0.75–0.95) | 0.004       | 0.83(0.74–0.93) | 0.001       |
| 55–64 years          | 0.85(0.78–0.94) | 0.002       | 0.85(0.77–0.93) | 0.001       |
| 65–74 years          | 0.90(0.82–1.00) | 0.039       | 0.89(0.81–0.98) | 0.020       |
| 75–84 years          | 0.92(0.83–1.01) | 0.070       | 0.90(0.82–0.99) | 0.025       |
| ≥ 85 years           | 1.00    |                | 1.00    |                |
| **Stroke type**      |         |                |         |                |
| Ischemic stroke      | 1.00    |                | 1.00    |                |
| Hemorrhagic stroke   | 1.19(1.04–1.36) | 0.012       | 1.18(1.03–1.35) | 0.019       |
| **Comorbidity category** |   |                |         |                |
| None                 | 1.00    |                | 1.00    |                |
| Moderate             | 1.06(1.00–1.12) | 0.055       | 1.06(1.00–1.12) | 0.070       |
| Severe               | 1.12(1.02–1.24) | 0.018       | 1.14(1.01–1.23) | 0.027       |
| Very severe          | 1.09(0.99–1.20) | 0.058       | 1.13(1.03–1.23) | 0.013       |
| **Admission year**   |         |                |         |                |
| 2010                 | 1.20(1.04–1.37) | 0.011       | 1.20(1.04–1.38) | 0.010       |
| 2011                 | 1.18(1.04–1.34) | 0.012       | 1.18(1.04–1.34) | 0.013       |
| 2012                 | 1.16(1.03–1.31) | 0.016       | 1.15(1.02–1.30) | 0.026       |
| 2013                 | 1.14(1.01–1.29) | 0.038       | 1.13(1.00–1.27) | 0.055       |
| 2014                 | 1.07(0.94–1.22) | 0.307       | 1.07(0.94–1.22) | 0.315       |
| 2015                 | 1.02(0.95–1.23) | 0.258       | 1.06(0.93–1.21) | 0.347       |
| 2016                 | 1.01(0.90–1.15) | 0.793       | 1.02(0.90–1.15) | 0.816       |
| 2017                 | 1.00(0.87–1.13) | 0.916       | 1.00(0.88–1.14) | 0.968       |
| 2018                 | 1.03(0.91–1.16) | 0.667       | 1.02(0.90–1.16) | 0.745       |
| 2019                 | 0.97(0.86–1.10) | 0.658       | 0.97(0.86–1.10) | 0.634       |
| 2020                 | 1.00    |                | 1.00    |                |
| **Payer, N (%)**     |         |                |         |                |

Model 1: unadjusted length of stay; Model 2: length of stay after adjusting age, sex, stroke types, calendar year, comorbidity categories.
To further control confounding factors, we conducted the multivariate analysis, and adjusted the age, stroke types, comorbidity categories, and admission year. There was also a positive correlation LOS and comorbidity burden. Compared to the elder aged 85 years and more, the younger had less LOS with a statistical significance except for the 18–34 years age group. And the mean LOS in the younger groups was lower by 10%, 11%, 10.2%, 15%, 17%, and 20% for those between 75 and 84 years, 65 and 74 years, 55 and 64 years, 45 and 54 years, and 35 and 44 years, respectively. The LOS of hemorrhagic stroke was higher by 19% than that of ischemic stroke. There is significant 20 percent points decrease of the LOS in calendar year 2020 compared with ten years ago.

### Inpatient Costs

The overall unadjusted median hospitalization expense was 15151.7RMB (IQR: 10649.7-22584.9RMB), which was equivalent to $2307.6 (IQR: $1621.9-$3439.7) based on an exchange rate of 6.57 RMB for per United States dollar. No inpatient cost difference was found between ischemic stroke and hemorrhagic stroke (15190.8RMB, IQR: 10696.1-22563.8RMB vs. 14694.9 RMB, IQR: 10023.1-22997.7RMB). The median of cost in the four comorbidity groups was 14160.4RMB ($2156.6), 15243.5RMB ($2321.5), 17936.7RMB ($2731.8), and 19339.3RMB ($2945.4), respectively (Table 1). Patients with very severe comorbidity spend the most money. The elder aged ≥ 85 years expensed more than the rest any age groups except for the youngest group. Compared to those without comorbidity, it was obvious that patients carried very severe comorbidity needed to spend the extra 27% expense. Admission on weekday had greater hospital expenses than those with weekend admission. And compared to 2020, the mean inpatient cost was higher by 36% for the cost in 2010. Season and medical payment methods had no effect on cost (Table 5).
Table 5
Estimated Hospital Cost With 95% Confidence Intervals by Characteristics

|                        | Model 1       |           | Model 2       |           |
|------------------------|---------------|-----------|---------------|-----------|
|                        | B (95%CI)     | P value   | B (95%CI)     | P value   |
| Sex                    |               |           |               |           |
| Male                   | 1.00          |           | 1.00          |           |
| Female                 | 1.07(1.04–1.10) | <0.001    | 1.00(0.97–1.03) | 0.914    |
| Age group              |               |           |               |           |
| 18–34 years            | 0.79(0.62–1.03) | 0.077     | 0.80(0.63–1.01) | 0.061    |
| 35–44 years            | 0.71(0.63–0.80) | <0.001    | 0.76(0.68–0.85) | <0.001   |
| 45–54 years            | 0.67(0.62–0.71) | <0.001    | 0.74(0.69–0.79) | <0.001   |
| 55–64 years            | 0.70(0.66–0.75) | <0.001    | 0.75(0.71–0.79) | <0.001   |
| 65–74 years            | 0.77(0.73–0.82) | <0.001    | 0.82(0.77–0.86) | <0.001   |
| 75–84 years            | 0.82(0.78–0.87) | <0.001    | 0.88(0.83–0.93) | <0.001   |
| ≥ 85 years             | 1.00          |           | 1.00          |           |
| Comorbidity Category   |               |           |               |           |
| None                   | 1.00          |           | 1.00          |           |
| Moderate               | 1.12(1.08–1.16) | <0.001    | 1.11(1.07–1.14) | <0.001   |
| Severe                 | 1.36(1.28–1.43) | <0.001    | 1.23(1.16–1.29) | <0.001   |
| Very severe            | 1.40(1.33–1.48) | <0.001    | 1.27(1.21–1.39) | <0.001   |
| Week                   |               |           |               |           |
| Weekend                | 0.96(0.93–1.00) | 0.029     | 0.96(0.93–0.99) | 0.006    |
| Weekday                | 1.00          |           | 1.00          |           |
| Admission year         |               |           |               |           |
| 2010                   | 0.61(0.56–0.66) | <0.001    | 0.64(0.59–0.69) | <0.001   |
| 2011                   | 0.63(0.58–0.67) | <0.001    | 0.65(0.61–0.70) | <0.001   |
| 2012                   | 0.53(0.50–0.57) | <0.001    | 0.55(0.52–0.59) | <0.001   |
| 2013                   | 0.62(0.58–0.66) | <0.001    | 0.65(0.60–0.69) | <0.001   |
| 2014                   | 0.72(0.67–0.77) | <0.001    | 0.73(0.68–0.79) | <0.001   |
| 2015                   | 0.76(0.71–0.82) | <0.001    | 0.78(0.73–0.83) | <0.001   |
| 2016                   | 0.77(0.72–0.82) | <0.001    | 0.78(0.73–0.83) | <0.001   |
| 2017                   | 0.83(0.78–0.90) | <0.001    | 0.84(0.79–0.90) | <0.001   |
| 2018                   | 0.98(0.91–1.05) | 0.537     | 0.99(0.93–1.06) | 0.866    |
| 2019                   | 1.00(0.93–1.07) | 0.974     | 1.01(0.94–1.07) | 0.878    |
| 2020                   | 1.00          | 1.00      | 1.00          | 1.00     |
| Stroke type            |               |           |               |           |
| Ischemic stroke        | 1.01(0.93–1.09) | 0.863     | -             | -        |

Model 1: unadjusted in-hospital cost; Model 2: in-hospital cost after adjusting age, sex, week, calendar year, comorbidity category.
|                      | Model 1         | Model 2         |
|----------------------|-----------------|-----------------|
| Hemorrhagic stroke   | 1.00            |                 |
| **Payer**            |                 |                 |
| Urban Employee Basic Medical | 1.00 (0.94–1.05) | 0.855 (0.78–0.93) |
| Urban Residence Basic Medical Insurance | 0.94 (0.88–1.01) | 0.073 (0.04–0.12) |
| Self-Pay             | 1.00            |                 |
| **Season**           |                 |                 |
| Spring               | 1.02 (0.97–1.06) | 0.456 (0.35–0.58) |
| Summer               | 1.02 (0.98–1.07) | 0.351 (0.27–0.45) |
| Fall                 | 1.05 (1.01–1.10) | 0.028 (0.01–0.05) |
| Winter               | 1.00            |                 |

Model 1: unadjusted in-hospital cost; Model 2: in-hospital cost after adjusting age, sex, week, calendar year, comorbidity category.

**Discussion**

This study first evaluated eleven-year trends in first-time stroke with comorbidity, and the effect of comorbidity on mortality, length of stay, and hospital cost from 2010 to 2020 in Tianjin, north of China. We have three main findings: the age group of first stroke patients was concentrated from 55 to 84 years old during the eleven years, and the population of the old elderly (≥ 85 years old) was increasing with the deepening of aging society; there was a decreased trend of those with no and moderate comorbidity, and an increased tendency of patients with severe and very severe comorbidity; those with severe and very severe comorbidity had higher in-hospital and 7-day mortality, longer LOS and more heavy economic burden, especially in the patients aged 55 to 65 years.

We observed that tendency of comorbidity increasing and aging populations was in line with the study in a developed country of Denmark. While a more serious aging trend in Denmark was observed with the predominance of first-stroke people aged ≥ 70 years (almost 63%), and patients aged 65 years old was the dominant for those with ischemic stroke. Therefore, it was important to pay attention to impact of comorbidity on stroke in an aging society. Although less attention was paid to comorbidity, there were several previous studies in other countries devoted to comorbidity. Higher CCI scores were generally associated with worse function outcome at hospital discharge and greater 1-year mortality of stroke. Some national studies with a large sample size concluded that comorbidity was a strong prognosis predicted factor for not only short-term prognosis, but also 5-year mortality regardless of stroke subtype.

A cohort study in Australia divided 776 stroke patients into high and low CCI scores group and found that a higher CCI score as a risk factor increased in-hospital mortality, LOS, and inpatient cost, which was consistent with our study. Different from those, the mean age in our study was younger (69.3 years vs 80.1 years), LOS were longer (14 days vs 5.44 days), and mortality in heavy comorbidity burden was lower (19.5% vs 22.1%). The reason for differences may be from the different regions, degree of social aging, national medical development levels, medical insurance policies, and sample size. Compared to the developing countries, Australia had the deeper degree of social aging and better health-care systems. Furthermore, patients aged 80 years old or older had more comorbidities and higher mortality than in those younger than 80 years, which further supported that our mortality rate is slightly lower than Australia's. However, different sample size may be contributed to the results differences, with 5988 patients in our patients larger than 776 population in theirs.

First stroke inpatient mortality in our study was lower than the national study in our country based on community and a sample size of 0.5 million adults (4.2% vs 11%)². For one thing, the latter study based on the big data had more regional diversity, younger population (59.3 vs 69.3 years), and higher proportion of hemorrhage stroke than ours (18% vs 4%). For another thing, the national data estimated...
the 28-day mortality, while in-hospital mortality in ours. Post-hospital death events may result in the increased mortality. Besides, the big data supported that mortality of hemorrhage stroke was higher than that of ischemic stroke, with the ratio of 11% higher than 3% in our study. A nationwide inpatient data from America also reported that more comorbidities and older age were independently associated with in-hospital mortality. Other studies found that women were related to the increased risk of in-hospital death. In our study, there was no significance in the multivariable analysis, the differences of results may attribute to regional, racial differences, and the different sample size.

We further analyzed the relationship between comorbidity and in-hospital mortality by seasonal stratification and found that patients with severe and very severe comorbidity had higher risk than those without comorbidity no matter in which season, which was in line with a published study. Another 5-year hospital-based study on connection between season and stroke reported that stroke case-fatality rate was the highest in the winter especially in aged ≥ 65 years. While the seasonality of 7-day mortality was never seen in our study, we made an assumption that there was a time lag effect of mortality. It is reported that pneumonia had a higher prevalence in winter, and recent infection increased the mortality of stroke, which may explain the phenomenon of seasonal difference in our study with the older patients with exist of higher proportion of pneumonia.

After exploring in-hospital mortality associated with individual comorbidities in patients with first stroke, we found that patients with pneumonia occupied first place (HR, 15.06, 95% CI, 10.08–22.50, P<0.001), followed by moderate to severe renal (HR, 2.47, 95% CI, 1.50–4.08, P<0.001) and moderate to severe liver disease (HR, 2.58, 95% CI, 1.32–5.08, P = 0.006). The pneumonia may result from dysphagia leading to aspiration pneumonia, acroparalysis leading to long time of stay in bed and hypostatic pneumonia, and climate change in different season leading to respiratory infection. An England study showed that the aspiration pneumonia had a higher short-term mortality than those without aspiration pneumonia. It was validated effective and practicable to perform an early dysphagia screening by neurologist, speech–language therapists, or well-trained nurses. The results of several studies were consistent with our findings for association between in-hospital mortality and kidney dysfunction on admission and liver dysfunction. Therefore, these results remind us that patients with moderate to severe renal and liver dysfunction on admission and dysphagia need to be given targeted intervention strategies to improve their prognosis on discharge, especially the reasons resulting in pneumonia.

Different from previous studies, inpatient cost had no difference between ischemic and hemorrhage stroke in our study. This may be because conservative medical treatment without surgery in our neurology department. The older with heavy comorbidity burden tended to spend more money and experience longer LOS, which may be caused by that the older needed to pay money and time for the treatment of comorbidities and complications, such as pneumonia, abnormal renal and liver function. And our study demonstrated above hypothesis from a different angle that hospital cost become more higher with the increasing comorbidity burden from 2010 to 2020. Considering the clinical and economic impact among patients with first stroke with different comorbidity categories, especially in the elder with heavy comorbidity burden, the clinical physicians should systematically summarize the impact of age, sex, primary stroke disease, and comorbidity burden calculated by Charlson's comorbidity index, and propose management strategies aimed at reducing adverse effects as well as social and economic costs.

Several limitations of our study should be acknowledged. First, we conducted the analysis on our admission data according to ICD codes. It is possible that the exist of coding errors or omissions of diagnoses and complications resulted inaccurate classification of comorbidity. Secondly, some important covariates was unavailable, such as body mass index (BMI), personal history (smoking and drinking), subtypes and severity of stroke, thrombolytic therapy, drugs for comorbidities and laboratory results. Thirdly, to facilitate the analysis of in-hospital mortality, we assumed that discharged patients were still alive during the study period. Fourth, although the average LOS was 14 days according to the limitation of medical insurance policy, a longer hospital stay was still required among patients with heavy comorbidity burden. Finally, there was a selection bias considering that our study was a retrospective study at a single center, which may limit the generalisability of our findings. Despite these limitations, our study has its own strength and important implications. The results of a large sample from a comprehensive hospital are representative in Tianjin, and in north of China to some extent due to the similar climate, diet and lifestyle.

Conclusions

Patients with comorbidity were increasing in number, and comorbidity burden was a strong predicted factor for in-hospital mortality, LOS and inpatient cost, especially in patients aged 55 years or more.
Declarations

Ethics approval and consent to participate

Our study was approved by The Second Hospital of Tianjin Medical University Ethics Committee and the informed consents were not needed to sign.

Consent for publication

All authors consent to the publication of this manuscript; additional consent is not applicable.

Availability of data and materials

The datasets used or analysed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

RH collected the data, performed the statistical analysis and drafted the manuscript. XQ performed some statistical analysis and revised the manuscript. XX and LW revised the manuscript. XL designed the study, double-checked the statistical analysis and revised the manuscript.

Acknowledgements and Sources of Funding

This study was supported by the Key Technology Research and Development Program of Science and Technology, Tianjin (18ZXDBSY00210), Research and promotion project of appropriate technology for intervention of high risk population of stroke in China (2020R0005), and Clinical Medicine Research Project of the Second University of Tianjin Medical University (2020LC04).

Disclosure

The author reports no conflicts of interest in this work.

References

1. Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D, et al. Global, regional, and national burden of stroke, 1990–2016: A systematic analysis for the global burden of disease study 2016. The Lancet Neurology. 2019;18:439-458
2. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: A systematic analysis for the global burden of disease study 2017. The Lancet. 2019;394:1145-1158
3. Chen Y, Wright N, Guo Y, Turnbull I, Kartsonaki C, Yang L, et al. Mortality and recurrent vascular events after first incident stroke: A 9-year community-based study of 0.5 million Chinese adults. The Lancet Global Health. 2020;8:e580-e590
4. Li Z, Jiang Y, Li H, Xian Y, Wang Y. China’s response to the rising stroke burden. BMJ. 2019;364:l879
5. China. State Statistical B. Communique of the major statistics from the first national population census as released by the state statistical bureau of the people's republic of China (November 1, 1954). Chin Sociol Anthropol. 1984;16:62-65
6. Zhao Y, Smith JP, Strauss J. Can China age healthily? The Lancet. 2014;384:723-724
7. Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, incidence, and mortality of stroke in China: Results from a nationwide population-based survey of 480,687 adults. Circulation. 2017;135:759-771
8. Schmidt M, Jacobsen JB, Johnsen SP, Bøtker HE, Sørensen HT. Eighteen-year trends in stroke mortality and the prognostic influence of comorbidity. Neurology. 2014;82:340-350
9. Yafasova A, Fosbøl EL, Christiansen MN, Vinding NE, Andersson C, Kruuse C, et al. Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark (1996-2016). Neurology. 2020;95:e2343-e2353
10. Ofori-Asenso R, Zomer E, Chin KL, Si S, Markey P, Tacey M, et al. Effect of comorbidity assessed by the charlson comorbidity index on the length of stay, costs and mortality among older adults hospitalised for acute stroke. Int J Environ Res Public Health. 2018;15

11. Yip WC-M, Hsiao WC, Chen W, Hu S, Ma J, Maynard A. Early appraisal of china's huge and complex health-care reforms. The Lancet. 2012;379:833-842

12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of chronic diseases. 1987;40:373-383

13. Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson index comorbidity adjustment for ischemic stroke outcome studies. Stroke. 2004;35:1941-1945

14. Ong C-T, Sung S-F, Wong Y-S, Wu C-S, Hsu Y-C, Su Y-H, et al. Risk factors for in-hospital mortality among ischemic stroke patients in southern taiwan. International Journal of Gerontology. 2016;10:86-90

15. Zhang L, Sun W, Wang Y, Wang X, Liu Y, Zhao S, et al. Clinical course and mortality of stroke patients with coronavirus disease 2019 in wuhan, china. Stroke. 2020;51:2674-2682

16. Goudie A, Dynan L, Brady PW, Rettiganti M. Attributable cost and length of stay for central line-associated bloodstream infections. Pediatrics. 2014;133:e1525-1532

17. Tessier A, Finch L, Daskalopoulou SS, Mayo NE. Validation of the charlson comorbidity index for predicting functional outcome of stroke. Arch Phys Med Rehabil. 2008;89:1276-1283

18. Corraini P, Szepligeti SK, Henderson VW, Ording AG, Horvath-Puho E, Sorensen HT. Comorbidity and the increased mortality after hospitalization for stroke: A population-based cohort study. J Thromb Haemost. 2018;16:242-252

19. Marini C, Baldassarre M, Russo T, De Santis F, Sacco S, Ciancarelli I, et al. Burden of first-ever ischemic stroke in the oldest old: Evidence from a population-based study. Neurology. 2004;62:77-81

20. Oviagele B. Nationwide trends in in-hospital mortality among patients with stroke. Stroke. 2010;41:1748-1754

21. Alhazzani AA, Mahfouz AA, Abolyazid AY, Awadalla NJ, Katramiz K, Faracheen A, et al. In hospital stroke mortality: Rates and determinants in southwestern saudi arabia. Int J Environ Res Public Health. 2018;15

22. Diaz A, Gerschcovich ER, Diaz AA, Antia F, Gonorazky S. Seasonal variation and trends in stroke hospitalizations and mortality in a south american community hospital. J Stroke Cerebrovasc Dis. 2013;22:e66-69

23. Wang Y, Levi CR, Attia JR, D’Este CA, Spratt N, Fisher J. Seasonal variation in stroke in the hunter region, australia: A 5-year hospital-based study, 1995-2000. Stroke. 2003;34:1144-1150

24. Lieberman D, Lieberman D, Friger MD. Seasonal variation in hospital admissions for community-acquired pneumonia: A 5-year study. J Infect. 1999;39:134-140

25. Becher H, Grau A, Steindorf K, Buggle F, Hacke WJEB. Previous infection and other risk factors for acute cerebrovascular ischaemia: Attributable risks and the characterisation of high risk groups. 2000;5:277-283

26. Teh WH, Smith CJ, Barlas RS, Wood AD, Bettencourt-Silva JH, Clark AB, et al. Impact of stroke-associated pneumonia on mortality, length of hospitalization, and functional outcome. Acta Neurol Scand. 2018;138:293-300

27. Palli C, Fandler S, Doppelhofer K, Niederkorn K, Enzinger C, Vetta C, et al. Early dysphagia screening by trained nurses reduces pneumonia rate in stroke patients: A clinical intervention study. Stroke. 2017;48:2583-2585

28. El Husseini N, Fonarow GC, Smith EE, Ju C, Schwamm LH, Hernandez AF, et al. Renal dysfunction is associated with poststroke discharge disposition and in-hospital mortality: Findings from get with the guidelines-stroke. Stroke. 2017;48:327-334

29. Fabbian F, Gallerani M, Pala M, De Giorgi A, Salmi R, Dentali F, et al. Association between in-hospital mortality and renal dysfunction in 186,219 patients hospitalized for acute stroke in the emilia-romagna region of italy. Angiology. 2014;65:906-910

30. Parikh NS, Merkler AE, Schneider Y, Navi BB, Kamel H. Discharge disposition after stroke in patients with liver disease. Stroke. 2017;48:476-478

31. Ma Z, Deng G, Meng Z, Wu H. Hospitalization expenditures and out-of-pocket expenses in patients with stroke in northeast china, 2015-2017: A pooled cross-sectional study. Front Pharmacol. 2020;11:596183

32. Ng CS, Toh MP, Ng J, Ko Y. Direct medical cost of stroke in singapore. Int J Stroke. 2015;10 Suppl A100:75-82

33. Rha JH, Koo J, Cho KH, Kim EG, Oh GS, Lee SJ, et al. Two-year direct medical costs of stroke in korea: A multi-centre incidence-based study from hospital perspectives. Int J Stroke. 2013;8:186-192
Figures

![Figure 1](image)

**Figure 1**

In-hospital mortality associated with individual comorbidities and complications after first-time hospitalization for stroke.

### Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SUPPLEMENTALMATERIAL.docx](#)
- [supplementaryfigure1.tif](#)
- [supplementaryfigure2.tif](#)